Sec. 404. Reauthorization; reporting requirements
74 words·~1 min read·
/bill/117/s/4535/is/section-404A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 744I of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–53 ) is amended— by striking 2018 each place it appears and inserting 2023 ; by striking Biosimilar User Fee Amendments of 2017 each place it appears and inserting Biosimilar User Fee Amendments of 2022 ; in subsection (a)(4), by striking 2020 and inserting 2023 ; and in subsection (f), by striking 2022 each place it appears and inserting 2027 .
Connections1 off-index
1 reference not yet in our index
- 21 USC 379j–53
Citation graph
cites case law
Sec. 404
Reauthorization; reporting requirements
Cite21 USC 379j–53
Cites 1Cited by 0 across 0 sources